Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 8/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 6/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5285031 | 0.76 | BCAT2 (0.54) | SMN1; SMN2HPGDL3MBTL1RAB9AATM | |
| SCHEMBL157777 | 0.76 | HPGD (0.70) | PKMGSK3BSMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL3053745 | 0.73 | PKM (0.67) | PKMGSK3BSMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL5281555 | 0.72 | ALOX5 (0.42) | PKMGSK3BSMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL5889623 | 0.72 | HDAC1 (0.35) | SMN1; SMN2HPGDRAB9ANPC1POLB | |
| SCHEMBL632902 | 0.71 | PKM (0.49) | PKMGSK3BSMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL18885432 | 0.71 | KMT2A (0.50) | PKMSMN1; SMN2HPGDRAB9ANPC1 | |
| SCHEMBL20406859 | 0.71 | SMN1; SMN2 (0.49) | PKMGSK3BSMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL5966728 | 0.71 | ALOX5 (0.43) | PKMGSK3BSMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL3289108 | 0.71 | GSK3B (0.61) | PKMGSK3BSMN1; SMN2HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | PKM 4619/4885GSK3B 4199/4885SMN1; SMN2 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.